Cardiometabolic Effects of Rapid Glucose Excursion

Not Applicable

• Conditions: Diabetes Mellitus, Experimental

• Registration Number: NCT04488848
• Lead Sponsor: Barmherzige Brüder Linz

Brief Summary

The effects of rapid glucose excursions, induced by intravenous bolus application of glucose in healthy probands, on cardiometabolic and inflammatory parameters will be investigated

Detailed Description

BACKGROUND: It is well known that people with diabetes have a five times higher risk of dying of cardiovascular death than non-diabetics. However not only hyperglycaemia per se but also glycaemic variability is currently particularly regarded as a risk factor for cardiovascular and microvascular complications. Intermittent blood sugar excursions with pronounced fluctuations between high and low values instead of constant, even increased blood sugar exposure, have been shown to be more harmful in several studies.

AIM: The aim of this study is to determine the effect of rapid glucose excursion versus continuous glucose infusion on cardiovascular and metabolic parameters in healthy volunteers.

METHODS/DESIGN: In this study, ten healthy male subjects will be studied on two occasions. In a random order the subjects will receive 3 times 20 grams of glucose intravenously as a bolus or, on the other occasion, 60 grams of glucose continuously over 3 hours. Cardiometabolic biomarkers will be analysed serially to analyse the effects of glucose excursions.

PROSPECT: Glycaemic variability may be a crucial factor in the development of diabetic complications, but there is currently a lack of conclusive evidence. The causes and mechanisms of these negative influences on the cardiovascular system due to high glucose variability have not been sufficiently investigated and are therefore not fully understood so far. To date, however, there have been no studies with acutely altered glucose concentrations in healthy volunteers that have investigated the effects on traditional as well as recently identified cardiovascular and metabolic biomarkers. Knowledge of such effects may improve the therapeutic strategy in diabetic patients.

Study Timeline

• Study Start: 2019-04-11
• Study First Submitted: 2019-08-07
• Study First Submitted QC: 2020-07-26
• Study First Posted: 2020-07-28
• Primary Completion: 2020-12-31
• Status Verified: 2021-01
• Last Update Submitted: 2021-01-25
• Last Update Posted: 2021-01-27
• Study Completion: 2021-07

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: Male
• Target Recruitment: 10

Inclusion Criteria

• Men aged 18 years or older with no disease history
• written informed consent

Exclusion Criteria

• receiving any medication
• probands who suffer from infectious disease

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: CROSSOVER

Primary Outcome Measures

Name	Time	Method
Interleukin-6	48 hours	measurement of the concentration of IL-6 (parameter of inflammation) in the serum over time following infusion

Trial Locations

Locations (1)

Barmherzige Brüder Linz - Innere Medizin; 🇦🇹 Linz, Austria